2 Dividend Stocks to Scoop Up Without Hesitation Right Now

VICI Properties is presented as a dividend-focused REIT owning 93 experiential assets (54 gaming, 39 other), with 100% occupancy, weighted-average lease term >40 years, CPI-linked rent escalators, an annual dividend of ~$1.80 (yield ~6.3%), Q3 2025 revenue of ~$1.01 billion (+4.4% YoY), AFFO/share $0.60 (+5.3%), cash ~$508M and free cash flow ~$586M. Bristol Myers Squibb is highlighted as a long-standing dividend payer (annual dividend $2.52; yield ~4.6%; 18-year streak of increases) with Q3 2025 revenue of $12.2 billion (+3% YoY) and net earnings of $2.2 billion (+81% YoY), while noting upcoming patent expirations for Eliquis (~2026) and Opdivo (~2028) and growth from newer drugs such as Reblozyl, Breyanzi and Camzyos.

Analysis

Market structure: VICI (REIT) and other landlord-style names are structural winners from durable, long-term triple-net leases with CPI escalators and a 40+-year WALE; they gain vs. operators if consumer spending softens. Bristol Myers (BMY) wins defensively from a diversified drug mix and an 18-year dividend growth streak, but faces concentrated revenue risk from Eliquis (patent cliff ~2026) and Opdivo (~2028). Cross-asset: REITs remain rate-sensitive — a 100bp move higher in the 10-year can compress NAV multiples by ~8–12% industry-wide; pharma carries lower rate sensitivity but higher event risk, affecting implied vols and corporate credit spreads.

Risk assessment: Key tail risks are a rapid rise in real yields (10yr >4.0% within 6 months) forcing cap-rate repricing, and tenant operational distress (e.g., operator bankruptcy) that could interrupt NNN cash flow despite lease structures. For BMY the low-probability high-impact risk is a generic Eliquis rollout removing $3–4B in revenue by 2027; upside catalyst is M&A or faster-than-expected growth in Reblozyl/Breyanzi. Immediate signals to watch: CPI prints (next 0–3 months), 10yr yield moves, and quarterly AFFO/coverage metrics.

Trade implications: Favor income-oriented long exposure to VICI sized 2–3% of portfolio on yields >=6% while hedging rate risk; prefer BMY at 1–2% with tail protection (12‑month puts) to blunt patent cliffs. Relative-value: go long VICI vs short operator CZR to isolate real-estate vs operational risk over a 3–12 month horizon. Options: use 9–12 month put spreads as affordable tail hedges for REIT exposure if 10yr >3.75%.

Contrarian angles: Market underweights embedded CPI rent escalators and the embedded duration of VICI cash flows — if inflation persists, nominal rent growth could offset cap-rate pressure. Conversely, consensus may underprice BMY’s pipeline/M&A optionality that could replace Eliquis cash flows; historical parallel: REITs re-rated after rate shocks (2013 taper) when long yields stabilized. Unintended consequence: crowding into high-yield REITs can amplify outflows if rates spike, creating a fast negative feedback loop.

Key Decisions for Investors

• Establish a 2–3% long position in VICI (VICI) on a yield >=6% or on a price pullback >5% within 30 days; hedge with a 9–12 month 10–15% OTM put or buy a 12-month put spread that pays off if 10yr >4.0% (time horizon 3–12 months).
• Initiate a 1.5–2% long position in Bristol Myers Squibb (BMY) and buy a 12-month put ~15% OTM to cap downside ahead of the 2026 (Eliquis) patent cliff; trim if Reblozyl/Breyanzi quarterly growth falls >20% QoQ or if company guidance misses by >5%.
• Implement a pair trade: long VICI (2.0% weight) vs short Caesars (CZR) (1.5% weight) to capture landlord vs operator spread over 3–12 months; unwind if CZR EBITDA margin improvement >300bps or VICI rent coverage (AFFO-to-rent) falls below 1.5x.
• Generate income on existing or new VICI positions by selling 3–6 month calls 5–7% OTM to collect premium (target effective yield uplift of 4–8% annualized); concurrently maintain a 6–12 month put spread as asymmetric tail protection if rates spike.